Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan

Journal of Dermatological Treatment

Volumn 16, Issue 1, 2005, Pages 37-42

  Feldman, S R ^a   Evans, C ^b   Russell, M W ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MAPI VALUES   (United States)

^c BIOGEN   (United States)

Author keywords

Medical costs; Pharmacy costs; Phototherapy; Psoriasis; Systemic therapy; Treatment failure

Indexed keywords

CYCLOSPORIN; ETRETIN; METHOTREXATE; NON PRESCRIPTION DRUG; PETROLATUM; PSORALEN; TAR;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL CHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL FEE; MEDICAL SERVICE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; TREATMENT FAILURE; ULTRAVIOLET B RADIATION; UNITED STATES;

ACITRETIN; ADULT; COSTS AND COST ANALYSIS; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MANAGED CARE PROGRAMS; METHOTREXATE; MIDDLE AGED; NEW ENGLAND; PHOTOTHERAPY; PSORIASIS; PUVA THERAPY; TREATMENT FAILURE; UNITED STATES;

EID: 14144249302     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630510025941     Document Type: Article

References (19)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
2. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422-5.
3. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999;26:723-33.
4. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138:686-8.
5. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol 2001;2:7-12.
6. Prescribing information for Soriatane® (acitretin) capsules. Nutley, NJ: Roche Pharmaceuticals; 2002.
7. Zachariae H, Sogaard H, Heickendroff L. Methotrexate-induced liver cirrhosis: clinical, histological and serological studies: a further 10-year follow-up. Dermatology 1996; 192:343-6.
8. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
9. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996;35:710-19.
10. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531-5.
11. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
12. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
13. Kraning KK, Odland GF. Psoriasis. J Invest Dermatol 1979;73:402-13.
14. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol 1984; 11:937-47.
15. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46: 850-60.
16. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802.
17. Feldman SR, Fleischer AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-9.
18. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
19. Mannino DM, Homa DM, Akinbawi LJ, et al. Surveillance for asthma: United States, 1980-1999. MMWR Surveill Summ 2002;51:1-13.